WuXi PharmaTech Supplies Laboratory Testing Services to Lee's Pharm

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-09-02-2015
Volume 11
Issue 9

WuXi's Laboratory Testing Division will be the exclusive supplier of laboratory testing services for Hong Kong-based Lee's Pharm.

WuXi PharmaTech and Lee's Pharm, a research-based biopharmaceutical company headquartered in Hong Kong with operations in China, announced on Aug. 26, 2015 that the two companies have signed an agreement whereby WuXi's Laboratory Testing Division (LTD) will be the exclusive supplier of laboratory testing services for Lee's Pharm. These services will include LTD's entire portfolio of discovery and investigational new drug/new drug application package services, including chemistry analytical services, in-vitro and in-vivo biology, oncology, immunology, in-vitro ADME (absorption, distribution, metabolism, and excretion) studies, pharmacokinetic/pharmacodynamic studies, toxicology, and clinical bioanalysis.  LTD will provide dedicated program management, streamline project coordination across WuXi, and allocate the necessary resources and R&D development efforts for Lee's Pharm programs.

"WuXi's impressive platform of lab testing services will allow our compounds to advance seamlessly through discovery, preclinical, and clinical development," Benjamin Li, executive director and CEO of Lee's Pharm, said in a press release.

Source: WuXi PharmaTech

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content